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Abstract
Previously we observed elevation of the serum concentration of two acute-phase protein (AFP)
complement components (C9 and C1-inhibitor) in patients with chronic hepatitis C who responded
(R) to IFN-a therapy, but not in non-responders (NR). In the present study we investigated the
effect of high-dose IFN-a therapy on serum concentrations of two positive [orosomucoid (OROSO)
and C-reactive protein (CRP)] and two negative [transferrin (TF) and fetuin/a2HS-glycoprotein
(AHSG)] AFP in an outpatient setting. We investigated blood samples of 40 patients with chronic
hepatitis C at the onset and at the end of a 3-month treatment with high-dose IFN-a2b (5 MIU/day
for 6 weeks, followed by 5 MIU t.i.w.) and of 52 healthy individuals. Serum concentrations of
OROSO, TF and AHSG were measured by radial immunodiffusion; CRP levels were determined by
immunotubridimetry. Compared to controls, patients with chronic hepatitis C had signi®cantly
lower OROSO and CRP, and higher AHSG levels. By the end of treatment, OROSO concentration
increased in R (P = 0.0054), but not in NR patients. In contrast, TF levels decreased in R (P =
0.0040), but did not change in NR patients. Similarly, in R patients, AHSG levels tended to decrease
(P = 0.0942) following IFN-a treatment. We conclude that the acute-phase reaction is suppressed in
patients with chronic hepatitis C that may be potentially related to the responsiveness to IFN-a
therapy.
Introduction
The pathomechanism of hepatic and extrahepatic manifest-
ations of hepatitis C virus (HCV) infection has been reviewed
extensively. Little is known, however, of the behavior of the
acute-phase reaction during chronic hepatitis caused by HCV.
Recently we found signi®cant increase in serum concentra-
tions of C9 and C1-inhibitor (C1-INH), two acute-phase
proteins (AFP) belonging to the complement system in
patients with chronic hepatitis C who responded to treatment
with IFN-a with at least 50% drop of HCV RNA concentration
(1). This observation has recently been con®rmed by
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Dumestre-Perard et al. (2) who observed a signi®cant increase
of the reduced C4 activity in chronic hepatitis C patients who
responded to IFN-a2b or IFN-a2b + ribavirin therapy. These
observations prompted us to determine serum levels of two
positive [orosomucoid (OROSO) and C-reactive protein
(CRP)] and two negative [transferrin (TF) and fetuin/a2HS-
glycoprotein (AHSG)] AFP in patients with chronic hepatitis C
prior to and following IFN-a therapy.
Methods
Forty patients with chronic hepatitis C (20 men and 20 women,
age 45.5 6 6.1 years, mean 6 SEM) were investigated. The
diagnosis of chronic HCV hepatitis was based on persistent
(>6 months) and elevated (>2-fold of the upper normal limit)
transaminase activities, and the presence of anti-HCV anti-
bodies and HCV RNA in their serum samples. Each patient
had a liver biopsy, which was done within 1 year (6.1 6 1.3
months, mean 6 SEM) before initiation of IFN-a treatment. The
mean duration of the disease was 48.5 6 50.9 months (mean
6 SEM). The initial histological activity of hepatitis assessed
by the Knodell index was 9.62 6 0.53 (mean 6 SEM). Blood
samples of 52 age-matched healthy blood donors (28 men
and 24 women, age 46.6 6 4.3 years, mean 6 SEM) were
used as controls. Patients received high-dose recombinant
IFN-a2b (Schering-Plough, Budapest, Hungary) 5 MIU s.c.
daily for 6 weeks followed by 5 MIU s.c. 3 times a week for a
further 6 weeks. Blood samples were taken before starting
therapy and at the end of the 3-month treatment. Patients were
considered as responders (R, n = 18) when a drop at least of
90% occurred in HCV RNA after 3 months of IFN therapy,
whereas those without such decrease were de®ned as non-
responders (NR, n = 22).
Serum concentrations of OROSO, TF and AHSG were
determined by radial immunodiffusion. Antisera to each
glycoprotein were raised in goats (DiaSorin; Stillwater,
Minnesota, MN, IgG fraction, cat. no. 81901, 91913 and
81931 for OROSO, TF and AHSG respectively). Variation
coef®cients were 4.2, 5.0 and 3.6% for OROSO, TF and AHSG
measurements, respectively. CRP levels were measured by
particle-enhanced immunoturbidimetric assays (Roche Cobas
Integra 4000). The detection limit of the assay was 0.07 mg/l
and the coef®cient of variation was 3.9% at 108 mg/l mean
value.
The concentration of HCV RNA was determined by the
branched-chain DNA method using the Quantiplex HCV
bDNA 2.0 kit (Bayer-Chiron, Emeryville, CA).
Non-parametric tests were used for the statistical analysis,
which was performed using GraphPad Prism version 3.0 (San
Diego, CA) and SPSS version 10 (Chicago, IL) for Windows.
Results
Serum concentrations of positive AFP OROSO and CRP and
negative AFP TF and AHSG in healthy controls and patients
with chronic hepatitis C before treatment with IFN-a
Serum concentrations of the AFP measured in patients before
treatment and healthy controls are shown in Table 1. Serum
OROSO levels were signi®cantly lower in patients with chronic
hepatitis C compared to those measured in control sera.
Serum CRP levels in patients' sera were within the reference
range (0±6 mg/l), although signi®cantly lower than those
measured in the controls. In contrast to the positive AFP,
concentration of the negative AFP AHSG was markedly higher
in patients with chronic hepatitis C than in healthy controls and
the mean concentration of the negative protein TF was higher
in patients than in controls.
Knodell index values exhibited signi®cant negative correl-
ation (r = ±0.398, P = 0.0190) to the OROSO levels, whereas no
correlation with other AFP was found.
Serum AFP and HCV RNA levels in patients with chronic
hepatitis C before and after treatment with IFN-a
When all patients were considered, at the end of the therapy
OROSO levels were slightly, but signi®cantly, increased
compared to pre-treatment values, while no signi®cant change
in CRP levels was observed (Table 1). IFN-a therapy resulted
in a signi®cant decrease in TF levels and a decrease in the
AHSG concentrations (Table 1). Serum HCV RNA decreased
signi®cantly from initial values following treatment.
Changes in serum concentrations of the positive AFP
OROSO and CRP and the negative AFP TF and AHSG in R
and NR patients
Only R patients showed a marked decrease in transaminase
activities (Table 2). Signi®cant differences in the changes of
the levels of some AFP tested were found between the R and
Table 1. Serum concentrations of AFP in patients with chronic hepatitis C and healthy blood donors
Controls
(n = 52)
HCV patients
before treatment
(n = 40)
P a HCV patients
after treatment
(n = 40)
P b P c
HCV RNA (MEQ/ml) 7.15 6 1.71 2.07 6 0.72 <0.0001
OROSO (mg/dl) 80.1 6 2.9 68.1 6 1.9 0.0008 73.0 6 1.7 0.084 0.0058
CRP (mg/l) 2.6 6 0.3 1.44 6 0.4 (n = 20) 0.0273 1.9 6 0.6 (n = 18) 0.0703 0.4668
TF (mg/dl) 257.0 6 9.1 282.0 6 10.0 0.3210 261.2 6 8.0 0.9153 0.0061
AHSG (mg/ml) 591.3 6 13.3 729.9 6 29.3 0.0001 698.8 6 20.8 <0.0001 0.0821
Values are expressed as mean 6 SEM.
aP controls versus patients before treatment, calculated by the Mann±Whitney test.
bP controls versus patients after treatment, calculated by the Mann±Whitney test.
cP patients versus before and after treatment, calculated by the Wilcoxon test.
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the NR groups (Table 2). In the R patients, serum OROSO
levels signi®cantly increased and returned to normal values
(Mann±Whitney test, P = 0.5017, 3-month values compared to
healthy controls), whereas in sera of NR patients no change
was observed and OROSO levels remained low by the end of
therapy (P = 0.0391, compared to controls). In contrast, no
changes in the CRP levels occurred either in the R or the NR
patients during therapy. There was a marked drop in the
concentration of TF during IFN-a treatment in the R patients,
whereas in NR patients no signi®cant changes in the TF levels
occurred. Serum AHSG levels decreased both in the R and NR
groups, but the difference was not statistically signi®cant
(Table 2).
Discussion
The chronic activation of the acute-phase reaction in liver
cirrhosis is well known (3). However, the behavior of the acute-
phase reaction in chronic HCV hepatitis has not been clari®ed.
In one study, no abnormalities in CRP, ®brinogen and albumin
levels were observed, whereas low C3 and C4 concentrations
were found that returned to normal in patients responsive to
IFN-a therapy (4). Similar results were reported for the C9 and
C1-INH levels by our group (1), and for C4 activity by
Dumestre-Perard et al. (2). Japanese authors did not ®nd
any correlation between CRP concentration and liver histolo-
gical activity (5). Serum TF levels have been studied only in
terms of hepatic iron load; the latter has been considered as a
risk factor contributing to severity of the disease and poor
response to IFN-a therapy (6,7). Although there was no
difference between TF concentrations in R and NR individuals,
a higher than normal iron saturation in the latter group has
been found (7).
Our results merit discussion in two aspects: (i) the difference
between healthy controls and patients with chronic hepatitis C,
and (ii) the difference in the changes of AFP levels between R
and NR to IFN-a therapy.
The comparison of values of healthy controls and those of
patients prior to therapy demonstrates decreased concentra-
tion of the positive AFP OROSO and increased levels of the
negative protein AHSG in chronic hepatitis patients prior to
treatment. Given its lower limit of zero, one cannot expect a
difference in the levels of the positive protein CRP that is both
biologically relevant and statistically signi®cant. However, the
fact that only seven out of 19 patients had CRP values >1 mg/l
and only two >6 mg/l gives the impression that CRP levels are
also decreased compared to controls. These ®ndings, in
accordance with the previous ®ndings of our group (1) and
others (2,4), indicate that in chronic hepatitis C the levels of at
least some AFP change to a direction that is opposite to that
observed in the acute-phase response.
In our patients, the consistent changes of the positive and
negative proteins suggest altered regulation in synthesis.
Altered removal from the circulation would affect both positive
and negative AFP levels to the same direction. Since we
observed different directions of change in serum concentra-
tion this mechanism does not seem to be signi®cant in our
study.
A decreased level of AHSG has been found in several
chronic liver diseases including alcoholic cirrhosis and
hepatocellular cancer, and proved to be a good predictor of
short-term mortality (8). Hepatitis B and Epstein±Barr virus-
induced acute hepatitis did not alter AHSG levels compared to
controls. The marked elevation of AHSG in chronic hepatitis C
patients is of particular interest in this respect. We think that
out of the four proteins we examined, AHSG is the best
indicator of altered control of liver protein synthesis in that
disease. Apart from osteogenesis imperfecta (9) and preg-
nancy (10,11), elevated AHSG levels have not been de-
scribed. It is important to remember that recently it has been
demonstrated that AHSG was in fact the product of two
different genes, which arose by tandem duplication (12). In
this respect, it would be of interest to study whether the
increase reported here is due to the expression of one or both
gene products, which substantially differ from each other.
The difference between the levels of the AFP of healthy
controls and chronic hepatitis C patients levels can be
explained in to ways: (i) the altered immune status of the
host induced by the acute viral infection and (ii) the direct
immunosuppressive effect of the virus. The infection induces a
Th1 cytokine pro®le dominance (IL-1 and IFN-g) that may
depress the synthesis of the AFP. However, this does not
seem to be a thorough explanation since positive AFP levels
are increased in many diseases that are characterized by Th1
dominance (e.g. rheumatoid arthritis or sarcoidosis).
There is increasing evidence that HCV has a direct
immunosuppressive effect on the host. Peripheral blood
mononuclear cells produce less IFN-a in the presence of
Table 2. Serum concentration of HCV RNA and AFP in patients with chronic hepatitis C prior to and following IFN-a
treatment
R (n = 18) NR (n = 22)
Before treatment After treatment P Before treatment After treatment P
HCV RNA (MEQ/ml) 8.05 6 3.2 0.06 6 0.05 0.0002 6.40 6 1.75 3.72 6 1.22 0.0749
OROSO (mg/dl) 67.0 6 2.6 75.2 6 1.8 0.0054 69.2 6 3.6 68.9 6 3.1 0.2617
CRP (mg/l) 1.3 6 0.5 (n = 10) 2.7 6 1.3 (n = 11) 0.8125 1.5 6 0.7 (n = 10) 1.4 6 0.4 (n = 17) 0.9102
TF (mg/dl) 296.1 6 17.8 262.2 6 13.7 0.0040 270.3 6 10.7 260.3 6 9.5 0.3176
AHSG (mg/ml) 717.4 6 45.9 690.6 6 35.5 0.0942 740.1 6 38.8 704.7 6 25.6 0.3349
ASAT/SGOT (U/l) 109.1 6 28.0 25.9 6 2.6 0.0156 77.4 6 9.10 63.1 6 12.1 0.9375
ALAT/SGPT (U/l) 138.3 6 19.6 43.9 6 8.1 0.0006 101.4 6 13.2 71.6 6 6.5 0.0175
Values are expressed as mean 6 SEM. Calculated by the Wilcoxon test.
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HCV (13). The NS3 antigen of the virus has been demon-
strated to induce proliferation of Th cells, but without produc-
tion of IL-2 (14). The strong negative correlation between the
Knodell histological index values and the OROSO levels also
indicate that a decrease in OROSO levels in chronic hepatitis
C is related to the pathological process occurring in the liver.
The paradoxical alteration of the AFP was reversed in
patients who responded well to IFN-a treatment, whereas it
persisted in NR. Changes may be explained by the direct
immunomodulatory effect of IFN-a. The fact that NR were
treated with the same doses of IFN-a, however, strongly
argues against this possibility. The reversion of the immuno-
suppressive effect of HCV resulting in restoration of the
regulation of the acute-phase reaction is another possibility.
This is supported by the observation that there is a stronger
cellular response and IFN production to recombinant HCV
core antigens in R than in NR patients (15). It is widely
accepted that a dominant Th1 cytokine pro®le is required to
eliminate HCV and a diminished Th1, a dominantly Th2 pro®le
supports the persistence of the virus (16). In accordance with
this, high levels of IL-10, a Th2 cytokine with a depressive
effect on Th1 function, are associated with more aggressive
hepatitis and a poor response to IFN-a therapy (13). On the
other hand, recent data suggest that the NS5A viral protein
may induce the synthesis of IL-8 (17) and a high IL-8
concentration is associated with a poor therapeutic response
to IFN-a (18). The induction of IL-8, along with other factors,
may be involved in the paradoxical alteration of the AFP
concentrations. We plan to address this assumption with
comparative measurements of IL-8 and AFP in patients with
chronic hepatitis C before and during IFN-a therapy.
It is tempting to speculate that the alteration of the AFP
levels we observed, regardless of its origin, could be used as
predictors of outcome of antiviral therapy in patients with
chronic C hepatitis. Obviously, further studies are needed to
determine the clinical value of AFP levels in predicting
successful antiviral therapy.
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